Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 7Sarcoma 3Gynecologic 3Thoracic 2Other solid neoplasm 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Recurrence 1Endometrial Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × rubitecan × Gynecologic × Clear all
NCT00006267 2013-07-09

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006230 2012-09-24

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
51 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00249990 2010-01-07

Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)

University of New Mexico

Phase 2 Completed
39 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡